Author

Jia-Horng Kao

April 18, 2023
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Summary Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts […]

Read More
February 16, 2022
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Summary Background Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods This analysis […]

Read More